A device with a battery, firmware, and an eventual end-of-life replacement surgery vs. a device with none of those problems at all.
Both categories are implanted, both stay in the body for years, and both have to clear the same biocompatibility and biostability bars — but past that, they're solving fundamentally different engineering problems. An active implant — a pacemaker, an implantable cardioverter-defibrillator, a spinal cord neurostimulator — contains a power source and electronics, runs firmware, and has a finite operating life dictated by its battery, which means a planned or unplanned replacement procedure is built into the device's lifecycle from day one. A passive implant — a hip stem, a mechanical or bioprosthetic heart valve, a vascular stent — has no power source at all; it performs a purely mechanical or biomaterial function, and its service-life question is about material fatigue and wear, not battery chemistry.
For an active implant, end of life is a scheduled electrical engineering event: battery chemistry (typically lithium-based for pacemakers, with different chemistries for higher-drain devices like defibrillators) has a known energy capacity, the device's power draw is characterized across sensing, pacing/stimulation, telemetry, and any therapy delivery, and the projected longevity — commonly years, engineered explicitly for a target replacement interval — is a design output, not an afterthought. Because the device stops functioning entirely when the battery depletes, active implants also require remote monitoring or periodic in-clinic interrogation to track battery status well before depletion, and firmware that can be updated or reconfigured without another surgery where the design allows it. For a passive implant, there is no analogous power budget — end of life is governed by fatigue life under millions of loading cycles, wear debris generation at articulating surfaces, or material degradation, all evaluated through mechanical testing rather than an electrical power model.
An active implant program needs electrical engineers designing ultra-low-power circuits, firmware engineers building safety-critical embedded software under IEC 62304, RF engineers handling wireless telemetry for remote monitoring, and battery/electrochemistry expertise to characterize and qualify the power source — on top of the mechanical and biomaterials work every implant needs. A passive implant program can be almost entirely mechanical and materials engineering: finite element stress analysis, fatigue testing to millions of cycles, wear-debris characterization, and surface treatment or coating development. This isn't a minor staffing difference — it's why active implantable medical devices are treated as their own regulatory and engineering subdiscipline (with dedicated standards like ISO 14708 for active implants specifically), and why a company that builds excellent passive orthopedic implants can't simply repurpose that team to build a neurostimulator without bringing in an entirely different set of engineering disciplines.
A passive implant's failure mode is typically gradual and probabilistic — fatigue crack initiation, progressive wear — governed by statistical material behavior under cyclic load. An active implant's dominant failure mode is different in kind: battery depletion is a deterministic energy-accounting problem with a projectable timeline the manufacturer can calculate from the power budget. That determinism is actually valuable — it's why active implants can be proactively replaced on a monitored schedule before failure, rather than discovered as an unplanned mechanical failure — but it only exists because there's a power source with a countable energy budget in the first place, something a passive implant structurally cannot have.
The active/passive distinction for implants is about the presence of a power source and electronics, not about mechanical motion. A mechanical heart valve has moving leaflets that open and close with every heartbeat, and a hip implant articulates with every step — both are still classified as passive implants, because neither contains a power source or electronics; they perform their mechanical function purely through material properties and geometry, powered entirely by the body's own physiology. "Active" specifically means the device itself contains a power source that drives its function.
Explains why active implants — pacemakers, implantable cardioverter-defibrillators, neurostimulators — which contain a power source, electronics, and firmware and therefore have a finite, projectable battery-driven end of life, are engineered as a fundamentally different discipline from passive implants — hip stems, heart valves, stents — which have no power source and perform a purely mechanical or biomaterial function whose end of life is governed by fatigue and wear.
The word 'active' invites confusion with mechanical motion — a moving heart valve leaflet or an articulating hip joint sounds more 'active' than a stationary component. The regulatory and engineering distinction is unrelated to motion: it's about whether the device contains its own power source and electronics. A device with moving parts but no power source (a mechanical heart valve) is passive. A device that's largely static but contains a battery and control electronics (a spinal cord stimulator) is active. The distinction tracks power source and electronics, not mechanical behavior.
Active implantable medical devices are subject to dedicated standards beyond general implant requirements — ISO 14708 covers general and device-specific requirements for active implantable devices, and firmware/software is subject to IEC 62304 software lifecycle requirements given its safety-critical role. Battery longevity is engineered as a power budget: the device's characterized current draw across all operating modes (sensing, therapy delivery, wireless telemetry) is divided into the battery's usable energy capacity to project service life, with monitoring built in to flag approaching depletion well before the device stops functioning. Passive implants instead undergo mechanical fatigue testing (commonly to millions of loading cycles simulating years of physiological use per relevant ASTM or ISO mechanical test standards) and wear-debris characterization to establish expected service life.
The active/passive distinction should shape program staffing and risk management from the earliest concept stage. An active implant program needs to budget for electrical, firmware, RF/telemetry, and battery/electrochemistry expertise alongside mechanical and biomaterials engineering, and its risk management has to explicitly address firmware failure modes, electromagnetic interference susceptibility, and battery depletion as distinct hazard categories. A passive implant program's risk management centers on mechanical failure modes — fatigue fracture, wear particle generation, loosening — with no electronics-related hazard category to manage. Conflating the two risk profiles, or assuming a team experienced with one implant type can directly transfer that experience to the other, is a common and costly planning mistake.
Both approaches exist. Traditional pacemakers and many ICDs use a sealed, non-rechargeable battery, and the entire pulse generator is surgically replaced (typically not requiring lead replacement) when the battery approaches depletion, commonly after several years. Some newer devices, particularly certain higher-power-draw neurostimulators, use rechargeable batteries with external wireless charging to extend the interval between surgical replacements, trading periodic patient-managed charging for fewer surgeries.
By definition, no — the presence of any power source and active electronics that drive the device's function is what defines the active category. A passive implant can, in principle, incorporate embedded passive sensors or markers (e.g., for imaging visibility) that don't require a power source, but the moment a device contains its own battery and active circuitry performing a function, it moves into the active implantable device category with its associated standards and engineering requirements.
General implant standards focus on biocompatibility, biostability, and mechanical performance — none of which address the hazards unique to a powered device: firmware failure modes, electromagnetic interference from other equipment (MRI scanners, security systems, industrial equipment), battery failure or depletion, and wireless telemetry security. ISO 14708's parts address these device-specific hazards directly, which general passive-implant-focused standards were never designed to cover.
Try our Biomedical Engineering
More calculators, simulators, and guides for this discipline.